A Patch Wearable Cardioverter-Defibrillator for Patients at Risk of Sudden Cardiac Arrest

被引:2
|
作者
Hummel, John [1 ]
Houmsse, Mahmoud [1 ]
Tomassoni, Gery [2 ]
Nair, Devi [3 ]
Romero, Jorge [4 ,5 ]
Hargrove, Joe [3 ]
Mathews, Kiran [6 ]
Thakkar, Anjali B. [7 ]
Ullery, Steven [8 ]
Eapen, Zubin J. [6 ]
Kumar, Uday N. [6 ]
Mehran, Roxana [9 ]
Butler, Javed [10 ,11 ]
机构
[1] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[2] Baptist Hlth Lexington, Lexington, KY USA
[3] St Bernards Heart & Vasc Ctr, Jonesboro, AR USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[5] Cardiol & Med Clin, Little Rock, AR USA
[6] Element Sci Inc, San Francisco, CA USA
[7] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA USA
[8] NAMSA, Minneapolis, MN USA
[9] Icahn Sch Med Mt Sinai, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA
[10] Baylor Scott & White Res Inst, 3434 Live Oak St, Dallas, TX 75204 USA
[11] Univ Mississippi, Dept Med, Jackson, MS USA
关键词
machine learning; sudden cardiac arrest; ventricular arrhythmia; wearable cardioverter defibrillator fi brillator; DEATH; PREVENTION; DISEASE;
D O I
10.1016/j.jacc.2024.04.063
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND For many patients, sudden cardiac arrest (SCA) risk is elevated temporarily. Wearable cardioverterdefibrillators (WCDs) can monitor and treat SCA during these temporary periods. Traditional WCDs can be uncomfortable, require frequent maintenance, and cannot be used when showering, resulting in poor compliance and avoidable SCA deaths. The Jewel is a novel, water-resistant patch-wearable cardioverter-defibrillator (P-WCD) with a machine learning detection algorithm designed to improve compliance and protection against SCA. OBJECTIVES This study aims to demonstrate the safety and clinical effectiveness of a novel P-WCD. METHODS The Jewel IDE Study, a prospective, single-arm study conducted at 30 U.S. sites, enrolled patients at SCA risk due to ventricular tachycardia/ventricular fibrillation who were not candidates for or refused an implantable defibrillator. The primary safety endpoint was <15% patients with clinically significant cutaneous adverse device effects and the primary effectiveness endpoint was <2 inappropriate shocks/100 patient-months. Secondary endpoints were >= 1 successful ventricular tachycardia/ventricular fibrillation conversion and wear time compliance of >14.1 h/d. RESULTS A total of 305 patients (mean age: 57.9 years; 30.2% female, 27.9% non-White) were enrolled, of which 290 had available device data. The clinically significant cutaneous adverse device effect rate was 2.30% (upper 1-sided 98% CI: 4.80); none were severe. No device-related deaths or serious adverse events were reported. The inappropriate shock rate was 0.36/100 patient-months (upper 1-sided 98% CI: 1.53). Of 11 shocks in 9 patients, 9 shocks were adjudicated to be appropriate. Eight of 9 shocks were successful with a single shock. Median wear time compliance was 23.5 (20.7-23.9) h/d. CONCLUSIONS The novel P-WCD is a safe and effective WCD with high patient compliance. There were no deaths due to noncompliance and a high number of successful conversions (Jewel IDE study [A Clinical Evaluation of the Jewel P-WCD in Subjects at High Risk for Sudden Cardiac Arrest]; NCT05201495) (J Am Coll Cardiol 2024;84:525-536) (c) 2024 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:525 / 536
页数:12
相关论文
共 50 条
  • [21] The wearable cardioverter-defibrillator is needed for most high-risk patients
    Lee, Byron K.
    HEART RHYTHM O2, 2020, 1 (03): : 227 - 229
  • [22] WEARABLE CARDIOVERTER - DEFIBRILLATOR IN PATIENTS WITH HIGH RISK OF SUDDEN CARDIAC DEATH: IS IT USEFUL A PATIENT SELECTION?
    Bolognesi, M.
    Rossi, L.
    Biagi, A.
    Coccia, M.
    Sticozzi, C.
    Comastri, G.
    Aschieri, D.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2022, 24 (SUPPL C)
  • [23] The wearable cardioverter-defibrillator is not needed for most high-risk patients
    Bhatt, Advay G.
    Mittal, Suneet
    HEART RHYTHM O2, 2020, 1 (03): : 230 - 233
  • [24] Underdetection of Ventricular Fibrillation by Wearable Cardioverter-Defibrillator Leading to Sudden Death
    Kokubun, Hiroto
    Miyauchi, Yasushi
    Inada, Shin
    Shimizu, Wataru
    CIRCULATION JOURNAL, 2021, 85 (01) : 79 - 79
  • [25] SURVIVORS OF SUDDEN CARDIAC ARREST IN THE PRESENCE OF MYOCARDIAL INFARCTION: SECONDARY PROTECTION WITH THE WEARABLE CARDIOVERTER DEFIBRILLATOR
    Bianco, Nicole R.
    Szymkiewicz, Steven
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A275 - A275
  • [26] Prevention of sudden cardiac death: The role of the implantable cardioverter-defibrillator
    Sinha, SK
    Mehta, D
    Gomes, JA
    MOUNT SINAI JOURNAL OF MEDICINE, 2005, 72 (01): : 1 - 9
  • [27] The US Experience of the Wearable Cardioverter-Defibrillator in Pediatric Patients
    Spar, David S.
    Bianco, Nicole R.
    Knilans, Timothy K.
    Czosek, Richard J.
    Anderson, Jeffrey B.
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2018, 11 (07):
  • [28] No Utility of the Wearable Cardioverter-Defibrillator in Patients With Nonischemic Cardiomyopathy?
    Klein, Helmut U.
    Zareba, Wojciech
    Kutyifa, Valentina
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (23) : 2807 - 2807
  • [29] The role of the implantable cardioverter-defibrillator for prevention of sudden cardiac death
    Josephson, ME
    Callans, DJ
    Buxton, AE
    ANNALS OF INTERNAL MEDICINE, 2000, 133 (11) : 901 - 910
  • [30] Do patients really wear their wearable cardioverter-defibrillator?
    Christ, M.
    Breker, I. M.
    Dierschke, W.
    Grett, M.
    Von Auenmueller, K. I.
    Trappe, H. -J.
    EUROPEAN HEART JOURNAL, 2014, 35 : 268 - 268